The Lyme Disease Test Kit Market is a dynamic market with diverse test type and component needs. Valued at USD 776.9 million in 2025 and projected to reach USD 1,200 million by 2035, the market is characterized by the leadership of ELISA and test kits, alongside the rapid emergence of PCR and reagents, driven by a focus on accuracy, early detection, and comprehensive diagnostic workflows.

Test Type Trends: ELISA Leads, PCR Emerges

The test type segment of the Lyme Disease Test Kit Market is diverse, encompassing ELISA, Western Blot, PCR, Rapid Tests, and Serology Tests. ELISA currently holds the largest share, favored for its sensitivity and capacity to process multiple samples simultaneously, making it an indispensable tool for screening. Western Blot is a significant segment, serving as a confirmatory test following initial screening, strengthening diagnostic accuracy. PCR is the fastest-growing segment, driven by its ability to detect the presence of the bacterium in the early stages, enhancing timely intervention.

Rapid Tests are gaining traction for their quick results, appealing in scenarios where immediate diagnosis is critical. The ongoing emphasis on early diagnosis is driving improvements across these test types.

Component Trends: Test Kits Dominate, Reagents Grow

The component segment is led by Test Kits, which represent a significant portion of the market, reflecting their critical role in confirming Lyme disease diagnoses. Reagents are a vital and growing segment, enabling accurate test results and supporting the functionality of test kits, witnessing robust growth due to advancements in testing technologies.

Consumables and Accessories also play essential roles. The market benefits from ongoing R&D emphasizing innovations aimed at enhancing testing accuracy and accessibility. As the Lyme Disease Test Kit Market continues to evolve, the growing emphasis on early, accurate, and accessible diagnostics will drive demand across these critical test type and component sectors.